sv3
As filed with the Securities and Exchange Commission on May 29, 2009
Registration No. 333-
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
STEMCELLS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
94-3078125 |
(State or other jurisdiction
|
|
(I.R.S. Employer |
of incorporation or organization)
|
|
Identification Number) |
3155 Porter Drive
Palo Alto, CA 94304
(650) 475-3100
(Address, including zip code, and telephone number, including area code of principal executive offices)
Kenneth B. Stratton, Esq.
General Counsel
StemCells, Inc.
3155 Porter Drive
Palo Alto, CA 94304
(650) 475-3100
(Name, address, including zip code, and telephone
number, including area code, of agent for service)
Please send copies of all communications to:
Geoffrey Davis, Esq.
Ropes & Gray LLP
One International Place
Boston, Massachusetts 02110
(617) 951-7000
Approximate date of commencement of proposed sale to the public: From time to time after the
effectiveness of the Registration Statement.
If the only securities being registered on this Form are being offered pursuant to dividend or
interest reinvestment plans, please check the following box: o
If any of the securities being registered on this Form are to be offered on a delayed or continuous
basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in
connection with dividend or interest reinvestment plans, check the following box: þ
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b)
under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. o
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act,
check the following box and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. o
If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective
amendment thereto that shall become effective upon filing with the Commission pursuant to Rule
462(e) under the Securities Act, check the following box. o
If this Form is a post-effective amendment to a registration statement filed pursuant to General
Instruction I.D. filed to register additional securities or additional classes of securities
pursuant to Rule 413(b) under the Securities Act, check the following box. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large
accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the
Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer o
|
|
Accelerated filer þ
|
|
Non-accelerated filer o
|
|
Smaller reporting company o |
|
|
|
|
(Do not check if a smaller reporting company) |
|
|
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposed maximum |
|
|
Proposed maximum |
|
|
|
|
|
Title of each class of securities to be |
|
|
Amount to be |
|
|
offering price per |
|
|
aggregate offering |
|
|
Amount of |
|
|
registered |
|
|
registered |
|
|
share (1) |
|
|
price (1) |
|
|
registration fee |
|
|
Common Stock, $.01 par value per share |
|
|
2,650,000 shares |
|
|
$1.65 |
|
|
$4,372,500 |
|
|
$244 |
|
|
|
|
|
(1) |
|
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c)
of the Securities Act of 1933, based on the average of the high and low prices as reported on
the Nasdaq Global Market on May 28, 2009. |
The Registrant hereby amends this registration statement on such date or dates as may be
necessary to delay its effective date until the Registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in
accordance with section 8(a) of the Securities Act of 1933 or until the registration statement
shall become effective on such date as the Securities and Exchange Commission, acting pursuant to
said section 8(a), may determine.
Information contained in this prospectus is not complete and may be changed. These securities may
not be sold until the registration statement filed with the Securities and Exchange Commission is
effective. This prospectus is not an offer to sell these securities and is not soliciting an offer
to buy these securities in any jurisdiction in which the offer or sale is not permitted.
|
|
|
PROSPECTUS
|
|
SUBJECT TO COMPLETION |
|
|
May 29, 2009 |
STEMCELLS, INC.
2,650,000 Shares of Common Stock
The stockholder listed on page 4 of this prospectus or in an accompanying supplement to this
prospectus is offering to sell up to 2,650,000 shares of our common stock.
We will not receive any proceeds from any such sale of these shares.
You should read this prospectus carefully before you invest in our securities. You should read
this prospectus together with additional information described under the heading Where You Can
Find More Information before you make your investment decision.
Our common stock is traded on the Nasdaq Global Market under the symbol STEM. On May 28,
2009, the closing price per share of our common stock was $1.63.
Investing in our securities involves risks. See Risk Factors beginning on page 3.
Neither the Securities and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or passed upon the adequacy or accuracy of this
prospectus. Any representation to the contrary is a criminal offense.
The date of this prospectus is May 29, 2009
TABLE OF CONTENTS
This prospectus is a part of a registration statement that we filed with the Securities and
Exchange Commission, or the SEC. The selling stockholder listed on page 4 of this prospectus may
offer to sell up to 2,650,000 shares of common stock. You should read both this prospectus,
including all documents incorporated herein by reference, together with additional information
described under Where You Can Find More Information.
You should rely only on the information contained in this prospectus. We have not authorized
anyone to give you information different from that contained in this prospectus. We are not making
an offer to sell these securities in any jurisdiction where the offer is not permitted. The
information contained in this prospectus is accurate only as of the date on the front cover of this
prospectus, regardless of when this prospectus is delivered or when any sale of our securities
occurs. Our business, financial condition, results of operations and prospects may have changed
since that date.
OUR COMPANY
StemCells, Inc. is engaged in the discovery and development of cell-based therapeutics to
treat damage to, or degeneration of, major organ systems. Our research and development (R&D)
programs are primarily focused on identifying and developing potential cell-based therapeutics
which can either restore or support organ function. In particular, since we relocated our corporate
headquarters and research laboratories to California in 1999, our R&D efforts have been directed at
refining our methods for identifying, isolating, culturing, and purifying the human neural stem
cell and human liver engrafting cells (hLEC) and developing these as potential cell-based
therapeutics for the central nervous system (CNS) and the liver, respectively. In our CNS Program,
our HuCNS-SC® product candidate (purified human neural stem cells) is in clinical development for
two indications. In January 2009, we completed a six patient Phase I clinical trial to evaluate the
safety and preliminary efficacy of HuCNS-SC cells as a treatment for infantile and late infantile
neuronal ceroid lipofuscinosis (NCL), two forms of a group of disorders often referred to as Batten
disease. In December 2008, the FDA approved our IND to initiate a Phase I clinical trial of
HuCNS-SC cells in a second indication, Pelizeaus-Merzbacher Disease (PMD), a fatal myelination
disorder in the brain. We expect the PMD trial to begin enrolling patients in 2009 and that the
trial will take 12-18 months to complete. In addition, our HuCNS-SC cells are in preclinical
development for spinal cord injury and retinal disorders. In our Liver Program, we are in
preclinical development with our human liver engrafting cells and we plan to seek the necessary
approvals to initiate a clinical experiment to evaluate hLEC as a potential cellular therapy, with
the initial indication likely to be liver-based metabolic disorders. For a brief description of our
significant therapeutic research and development programs see Overview Research and Development
Programs in the Business Section of Part I, Item 1 included in our Annual Report on Form 10-K for
the fiscal year ended December 31, 2008. We have also conducted research on several other cell
types and in other areas, which could lead to other possible product candidates, process
improvements or further research activities.
On April 1, 2009, we acquired substantially all of the operating assets and liabilities of
Stem Cell Sciences Plc. The acquired business includes proprietary cell technologies relating to
embryonic stem cells, induced pluripotent stem (iPS) cells, and tissue-derived (adult) stem cells;
expertise and infrastructure for providing cell-based assays for drug discovery; a media
formulation and reagent business; and an intellectual property portfolio with claims relevant to
cell processing, reprogramming and manipulation, as well as to gene targeting and insertion. This
acquisition positions us to pursue applications of our cell technologies to develop cell-based
research tools, which we believe represent nearer-term commercial opportunities.
Our principal executive offices are located at StemCells, Inc., 3155 Porter Drive, Palo Alto,
CA 94304 and our phone number is (650) 475-3100.
RISK FACTORS
You should consider the Risk Factors included under Part II, Item 1A of our most recent
Quarterly Report on Form 10-Q and our other reports filed with the SEC, which are incorporated by
reference in this prospectus. The risks and uncertainties we describe are not the only ones we
face. Additional risks not presently known to us, or that we currently deem immaterial, may also
impair our business operations. If any of these risks were to occur, our business, financial
condition, and results of operations could be severely harmed. This could cause the trading price
of our common stock to decline, and you could lose all or part of your investment.
FORWARD-LOOKING STATEMENTS
This prospectus and the documents incorporated in this prospectus by reference may contain
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended
(the Exchange Act). These statements may be identified by the use of forward-looking words or
phrases such as anticipate, believe, could, expect, intend, look forward, may,
planned, potential, should, will, and would. These forward-looking statements reflect
our current expectations and are based upon currently available data. The Private Securities
Litigation Reform Act of 1995 provides a safe harbor for such forward-looking statements. In
order to comply with the terms of the safe harbor, we note that a variety of factors could cause
actual results and experience to differ materially from the anticipated results or other
expectations expressed in the forward-looking statements.
1
Such statements include, without limitation, all statements as to expectation or belief and
statements as to our future results of operations; the progress of our research, product
development and clinical programs; the need for, and timing of, additional capital and capital
expenditures; partnering prospects; costs of manufacture of products; the protection of, and the
need for, additional intellectual property rights; effects of regulations; the need for additional
facilities; and potential market opportunities. Our actual results may vary materially from those
contained in such forward-looking statements because of risks to which we are subject, including
uncertainty as to whether the U.S. Food and Drug Administration (FDA) or other regulatory
authorities will permit us to proceed with clinical testing of proposed products despite the novel
and unproven nature of our technologies; the risk that our initial clinical trial and any other
clinical trials or studies could be substantially delayed beyond their expected dates or cause us
to incur substantial unanticipated costs; uncertainties in our ability to obtain the capital
resources needed to continue our current research and development operations and to conduct the
research, preclinical development and clinical trials necessary for regulatory approvals; the
uncertainty regarding our ability to obtain a corporate partner or partners, if needed, to support
the development and commercialization of our potential cell-based therapeutics products; the
uncertainty regarding the outcome of our Phase I clinical trial in NCL and any other clinical
trials or studies we may conduct in the future; the uncertainty regarding the validity and
enforceability of our issued patents; the uncertainty whether any products that may be generated in
our cell-based therapeutics programs will prove clinically safe and effective; the uncertainty
whether we will achieve revenue from product sales or become profitable; uncertainties regarding
our obligations with respect to our former encapsulated cell therapy facilities in Rhode Island;
obsolescence of our technologies; competition from third parties; intellectual property rights of
third parties; litigation risks; and other risks to which we are subject. All forward-looking
statements attributable to us or to persons acting on our behalf are expressly qualified in their
entirety by the cautionary statements and risk factors set forth in Risk Factors in this
prospectus.
The forward-looking statements included in this prospectus represent our estimates as of the
date of this prospectus. We specifically disclaim any obligation to update these forward-looking
statements in the future. These forward-looking statements should not be relied upon as
representing our estimates or views as of any date subsequent to the date of this prospectus.
2
USE OF PROCEEDS
The net proceeds from any disposition of the shares covered hereby would be received by the
selling stockholder. We will not receive any of the proceeds from any such sale of the common stock
offered by this prospectus.
3
SELLING STOCKHOLDER
We have prepared this prospectus to allow Asset Realisation Company Plc (formerly Stem Cell
Sciences Plc), or the selling stockholder, to sell, from time to time, up to 2,650,000 shares of
our common stock that we issued to it in exchange for our acquisition of substantially all of its
operating assets and liabilities on April 1, 2009. All of the common stock offered by this
prospectus may be offered by the selling stockholder for its own account. We will receive no
proceeds from any such sale of these shares by the selling stockholder.
The Acquisition
On April 1, 2009, we completed the acquisition of substantially all of the operating assets
and liabilities of Stem Cell Sciences Plc (SCS), the selling stockholder (which subsequently
changed its name to Asset Realisation Company Plc). As consideration for the acquisition, we
issued 2,650,000 shares of our common stock to the selling stockholder, which shares may be sold by
the selling stockholder pursuant to this prospectus. In addition, we had previously made two
secured loans to SCS in connection with our acquisition negotiations with SCS, and in connection
with the acquisition we waived the obligation of SCS to repay the principal and accrued interest of
these two loans. The principal and accrued interest for the two loans together totaled
approximately $709,000 as of March 31, 2009.
The shares were issued to the selling stockholder in a transaction exempt from registration
under the Securities Act in reliance on Rule 903 of Regulation S thereunder (Regulation S). The
selling stockholder represented that, at the time of the closing of the Acquisition, it was not a
U.S. Person, was not acquiring the shares for the account or benefit of any U.S. Person and
that the issuance of the shares was an offshore transaction (all within the meaning of Rule 902
of Regulation S).
The following table sets forth information with respect to our common stock known to us to be
beneficially owned by the selling stockholder as of May 28, 2009. To our knowledge, the selling
stockholder has sole voting and investment power over the common stock listed in the table below.
Except as otherwise disclosed herein, the selling stockholder, to our knowledge, has not had a
material relationship with us during the three years immediately preceding the consummation of the
acquisition.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common |
|
|
|
|
Beneficial Ownership of |
|
Stock |
|
Beneficial Ownership |
|
|
Common Stock Prior |
|
Saleable |
|
of Common Stock |
|
|
to the Offering (1) |
|
Pursuant |
|
After the Offering (1) |
|
|
Number of |
|
Percent of |
|
to This |
|
Number of |
|
Percent of |
Name of Selling Stockholder |
|
Shares |
|
Class |
|
Prospectus |
|
Shares |
|
Class |
Asset Realisation Company Plc |
|
|
2,650,000 |
(2) |
|
|
2(3) |
% |
|
|
2,650,000 |
(2) |
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Assumes that all of the shares held by the selling stockholder covered by this
prospectus are sold and that the selling stockholder acquires no additional shares of
common stock before the completion of this offering. However, as the selling
stockholder can offer all, some, or none of its common stock, no definitive estimate
can be given as to the number of shares that the selling stockholder will ultimately
offer or sell under this prospectus. |
|
(2) |
|
530,000 of the shares of our common stock subject to this registration statement are
held in escrow for the satisfaction of any claims arising out of our acquisition of
substantially all of the operating assets and liabilities of Stem Cell Sciences Plc.
Such shares will become saleable, if at all, only at the time of their release from
escrow. |
|
(3) |
|
Calculated based on 106,270,526 shares of common stock outstanding as of May 28, 2009. |
4
PLAN OF DISTRIBUTION
The selling stockholder may, from time to time, sell, transfer, or otherwise dispose of any or
all of its shares of common stock on any stock exchange, market, or trading facility on which the
shares are traded or in private transactions. These dispositions may be at fixed prices, at
prevailing market prices at the time of sale, at prices related to the prevailing market price, at
varying prices determined at the time of sale, or at negotiated prices.
The selling stockholder may use any one or more of the following methods when disposing of
shares or interests therein:
|
|
|
ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; |
|
|
|
|
block trades in which the broker-dealer will attempt to sell the
shares as agent, but may position and resell a portion of the block as
principal to facilitate the transaction; |
|
|
|
|
purchases by a broker-dealer as principal and resale by the broker-dealer for its account; |
|
|
|
|
an exchange distribution in accordance with the rules of the applicable exchange; |
|
|
|
|
privately negotiated transactions; |
|
|
|
|
broker-dealers may agree with the selling stockholder to sell a
specified number of such shares at a stipulated price per share; or |
|
|
|
|
a combination of any such methods of sale. |
The aggregate proceeds to the selling stockholder from any sale of the common stock offered by
it will be the purchase price of the common stock less discounts or commissions, if any. The
selling stockholder reserves the right to accept and, together with its agents from time to time,
to reject, in whole or in part, any proposed purchase of common stock to be made directly or
through agents. We would not receive any of the proceeds from any such sale.
The selling stockholder also may resell all or a portion of the shares in open market
transactions in reliance upon Rule 144 promulgated under the Securities Act, provided that it meets
the criteria and conform to the requirements of that rule.
The selling stockholder and any broker-dealers or agents that participate in the sale of the
common stock may be deemed to be underwriters within the meaning of Section 2(11) of the
Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the
shares may be underwriting discounts and commissions under the Securities Act. The selling
stockholder is subject to the prospectus delivery requirements of the Securities Act.
We have agreed with the selling stockholder to keep the registration statement, of which this
prospectus constitutes a part, effective until the earliest of (1) such time as all of the shares
covered by this prospectus have been disposed of pursuant to and in accordance with the
registration statement or (2) the date on which the shares can be sold pursuant to Rule 144
promulgated under the Securities Act (as such rule may be amended from time to time) without any
limitations under clauses (c), (e), (f) and (h) of Rule 144.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.
5
Nasdaq Global Market
Our common stock is listed for quotation on the Nasdaq Global Market under the symbol STEM.
WHERE YOU CAN FIND MORE INFORMATION
We have filed a registration statement on Form S-3 with the SEC for the stock we are offering
by this prospectus. This prospectus does not include all of the information contained in the
registration statement. You should refer to the registration statement and its exhibits for
additional information.
We are required to file annual and quarterly reports, special reports, proxy statements, and
other information with the SEC. We make these documents publicly available, free of charge, on our
website at www.stemcellsinc.com as soon as reasonably practicable after filing such documents with
the SEC. You can read our SEC filings, including the registration statement, on the SECs website
at http://www.sec.gov. You also may read and copy any document we file with the SEC at its public
reference facility at:
Public Reference Room
100 F Street N.E.
Washington, DC 20549.
Please call the SEC at 1-800-732-0330 for further information on the operation of the public
reference facilities.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The SEC allows us to incorporate by reference into this prospectus the information we file
with it, which means that we can disclose important information to you by referring you to those
documents. The information incorporated by reference is considered to be part of this prospectus,
and information in documents that we file later with the SEC will automatically update and
supersede information in this prospectus. We incorporate by reference the documents listed below
into this prospectus, and any future filings made by us with the SEC under Section 13(a), 13(c), 14
or 15(d) of the Exchange Act until we close this offering, including all filings made after the
date of the initial registration statement and prior to the effectiveness of the registration
statement. We hereby incorporate by reference the following documents:
|
|
|
Our Annual Report on Form 10-K for the year ended December 31, 2008 (File No.
000-19871); |
|
|
|
|
Our Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 (File
No. 000-19871); |
|
|
|
|
Our Current Reports on Form 8-K filed on March 3, 2009, March 30, 2009 and
April 1, 2009 (except the press release furnished therein) (File No. 000-19871); |
|
|
|
|
Our proxy statement on Schedule 14A filed with the SEC on April 30, 2009; and |
|
|
|
|
The description of our common stock contained in our registration statements on
Form 8-A (File No. 000-19871) filed August 3, 1998, under the Exchange Act, including
any amendment or report filed for the purpose of updating such description. |
You may request a copy of these filings, at no cost, by writing or telephoning us at the
following address:
StemCells, Inc.
3155 Porter Drive
Palo Alto, CA 94304
Attention: Investor Relations
Phone: (650) 475-3100
email: irpr@stemcellsinc.com
6
Copies of these filings are also available, without charge, on our Internet website at
www.stemcellsinc.com as soon as reasonably practicable after they are filed electronically with the
SEC. The information contained on our website is not a part of this prospectus.
LEGAL MATTERS
The validity of the issuance of the securities offered hereby will be passed upon for us by
Ropes & Gray LLP, Boston, Massachusetts.
EXPERTS
The consolidated balance sheets of StemCells, Inc. and its subsidiary as of December 31, 2008
and 2007, and the related consolidated statements of operations, changes in stockholders equity,
and cash flows for each of the three years in the period ended December 31, 2008, and managements
assessment of the effectiveness of internal control over financial reporting as of December 31,
2008, have been incorporated by reference herein and in the registration statement in reliance upon
the reports of Grant Thornton LLP, independent registered public accountants, upon the authority of
said firm as experts in accounting and auditing in giving said reports.
7
2,650,000 Shares of Common Stock
StemCells, Inc.
PROSPECTUS
May 29, 2009
We have not authorized any dealer, salesperson or other person to give any information or represent
anything not contained in this prospectus. You should not rely on any unauthorized information. If
anyone provides you with different or inconsistent information, you should not rely on it. This
prospectus does not offer to sell any shares in any jurisdiction where it is unlawful. Neither the
delivery of this prospectus, nor any sale made hereunder, shall create any implication that the
information in this prospectus is correct after the date hereof.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other expenses of Issuance and Distribution.
The following table sets forth the various expenses in connection with the sale and
distribution of the securities being registered. All amounts shown are estimates, except the SEC
registration fee. The registrant has agreed to pay these costs and expenses.
|
|
|
|
|
Securities and Exchange Commission registration fee |
|
$ |
244 |
|
Printing and engraving expenses |
|
$ |
1,000 |
* |
Legal fees and expenses |
|
$ |
10,000 |
* |
Accounting fees and expenses |
|
$ |
16,100 |
* |
|
Total |
|
$ |
27,344 |
* |
Item 15. Indemnification of Directors and Officers.
Section 145 of the Delaware General Corporation Law (DGCL) provides that a corporation may
indemnify any person who was or is a party or is threatened to be made a party to any threatened,
pending or completed action, suit or proceeding, whether civil, criminal or investigative (other
than an action by or in the right of the corporation) by reason of the fact that he is or was a
director, officer, employee or agent of the corporation, or is or was serving at the request of the
corporation as a director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise, against expenses (including attorneys fees), judgments, fines
and amounts paid in settlement actually and reasonably incurred by him in connection with such
action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be
in or not opposed to the best interests of the corporation, and, with respect to any criminal
action or proceeding, had no reasonable cause to believe his conduct was unlawful. Section 145
further provides that a corporation similarly may indemnify any such person serving in any such
capacity who was or is a party or is threatened to be made a party to any threatened, pending or
completed action or suit by or in the right of the corporation to procure a judgment in its favor,
against expenses actually and reasonably incurred in connection with the defense or settlement of
such action or suit if he acted in good faith and in a manner he reasonably believed to be in or
not opposed to the best interests of the corporation and except that no indemnification shall be
made in respect of any claim, issue or matter as to which such person shall have been adjudged to
be liable to the corporation unless and only to the extent that the Delaware Court of Chancery or
such other court in which such action or suit was brought shall determine upon application that,
despite the adjudication of liability but in view of all the circumstances of the case, such person
is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or
such other court shall deem proper.
Section 102(b)(7) of the DGCL permits a corporation to include in its certificate of
incorporation a provision eliminating or limiting the personal liability of a director to the
corporation or its stockholders for monetary damages for breach of fiduciary duty as a director,
provided that such provision shall not eliminate or limit the liability of a director (i) for any
breach of the directors duty of loyalty to the corporation or its stockholders, (ii) for acts or
omissions not in good faith or which involve intentional misconduct or a knowing violation of law,
(iii) under Section 174 of the DGCL (relating to unlawful payment of dividends and unlawful stock
purchase and redemption) or (iv) for any transaction from which the director derived an improper
personal benefit.
The Companys restated certificate of incorporation provides that the Companys Directors
shall not be liable to the Company or its stockholders for monetary damages for breach of fiduciary
duty as a director except to the extent that exculpation from liabilities is not permitted under
the DGCL as in effect at the time such liability is determined. The Companys restated certificate
of incorporation further provides that the Company shall indemnify its directors and officers to
the fullest extent permitted by the DGCL.
II-1
The Company has a liability insurance policy in effect which covers certain claims against any
officer or director of the Company by reason of certain breaches of duty, neglect, errors or
omissions committed by such person in his or her capacity as an officer or director.
Item 16. Exhibits.
See Exhibit Index beginning on page II-5 of this registration statement.
Item 17. Undertakings.
(a) The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective
amendment to this registration statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after the effective date of the
registration statement (or the most recent post-effective amendment thereof) which, individually or
in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered
(if the total dollar value of securities offered would not exceed that which was registered) and
any deviation from the low or high end of the estimated maximum offering range may be reflected in
the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the
changes in volume and price represent no more than 20 percent change in the maximum aggregate
offering price set forth in the Calculation of Registration Fee table in the effective
registration statement;
(iii) To include any material information with respect to the plan of distribution not
previously disclosed in the registration statement or any material change to such information in
the registration statement.
Provided, however, that the undertakings set forth in paragraphs (a)(1)(i), (a)(1)(ii) and
(a)(1)(iii) above do not apply if the registration statement is on Form S-3 or Form F-3 and the
information required to be included in a post-effective amendment by those paragraphs is contained
in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or
Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the
registration statements or is contained in a form of prospectus filed pursuant to Rule 424(b) that
is a part of the registration statement
(2) That, for the purpose of determining any liability under the Securities Act of 1933, each
such post-effective amendment shall deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the securities
being registered which remain unsold at the termination of the offering.
(b) That, for the purpose of determining liability under the Securities Act of 1933 to any
purchaser:
(1) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be
part of the registration statement as of the date the filed prospectus was deemed part of and
included in the registration statement; and
(2) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as
part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to
Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section
10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration
statement as of the earlier of the date such form of prospectus is first used after effectiveness
or the date of the first contract of sale of securities in the offering described in the
prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is
at that date an
II-2
underwriter, such date shall be deemed to be a new effective date of the registration statement
relating to the securities in the registration statement to which that prospectus relates, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof. Provided, however, that no statement made in a registration statement or prospectus that
is part of the registration statement or made in a document incorporated or deemed incorporated by
reference into the registration statement or prospectus that is part of the registration statement
will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or
modify any statement that was made in the registration statement or prospectus that was part of the
registration statement or made in any such document immediately prior to such effective date.
(c) That, for the purpose of determining liability of the registrant under the Securities Act
of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant
undertakes that in a primary offering of securities of the undersigned registrant pursuant to this
registration statement, regardless of the underwriting method used to sell the securities to the
purchaser, if the securities are offered or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to the purchaser and will be considered
to offer or sell such securities to such purchaser: (i) Any preliminary prospectus or prospectus of
the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; (ii)
any free writing prospectus relating to the offering prepared by or on behalf of the undersigned
registrant or used or referred to by the undersigned registrant; (iii) the portion of any other
free writing prospectus relating to the offering containing material information about the
undersigned registrant or its securities provided by or on behalf of the undersigned registrant;
and (iv) any other communication that is an offer in the offering made by the undersigned
registrant to the purchaser.
(d) The undersigned registrant hereby undertakes that: (i) for purposes of determining any
liability under the Securities Act of 1933, the information omitted from the form of prospectus
filed as part of the registration statement in reliance upon Rule 430A and contained in the form of
prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities
Act shall be deemed to be part of the registration statement as of the time it was declared
effective; and (ii) for the purpose of determining any liability under the Securities Act, each
post-effective amendment that contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof.
(e) The undersigned registrant hereby undertakes that, for purposes of determining any
liability under the Securities Act of 1933, each filing of the registrants annual report pursuant
to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable,
each filing of an employee benefit plans annual report pursuant to section 15(d) of the Securities
Exchange Act of 1934) that is incorporated by reference in the registration statement shall be
deemed to be a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof.
(f) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be
permitted to directors, officers and controlling persons of the registrant pursuant to the
foregoing provisions or otherwise, the registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public policy as expressed in
the Securities Act of 1933 and is therefore unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of
appropriate jurisdiction the question whether such indemnification by it is against public policy
as expressed in the Securities Act of 1933, and will be governed by the final adjudication of such
issue.
II-3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it
has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and
has duly caused this registration statement on Form S-3 to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Palo Alto, State of California, on the 29th
day of May, 2009.
|
|
|
|
|
|
StemCells, Inc.
|
|
|
By: |
/s/ Martin M. McGlynn
|
|
|
|
Name: |
Martin M. McGlynn |
|
|
|
Title: |
President and Chief Executive
Officer |
|
|
POWER OF ATTORNEY
Each person whose signature appears below constitutes and appoints Martin M. McGlynn and
Rodney K.B. Young, and each of them singly, his true and lawful attorney-in-fact and agent
with full power of substitution and resubstitution, for him and in his name, place
and stead, in any and all capacities, to sign any and all amendments (including post-effective
amendments) to this Registration Statement on Form S-3 to be filed by StemCells, Inc., and to file
the same, with all exhibits thereto, and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and
authority to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and
agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.
* * * *
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration
Statement has been signed by the following persons in the capacities and on the dates indicated:
|
|
|
|
|
/s/ Martin M. McGlynn
Martin M. McGlynn
|
|
President and Chief Executive
Officer and Director
(principal executive officer)
|
|
May 29, 2009 |
|
|
|
|
|
/s/ Rodney K.B. Young
Rodney K.B. Young
|
|
Chief Financial Officer
(principal financial officer)
|
|
May 29, 2009 |
|
|
|
|
|
/s/ George Koshy
George Koshy
|
|
Chief Accounting Officer
(principal accounting officer)
|
|
May 29, 2009 |
|
|
|
|
|
/s/ Eric Bejrkholt
Eric Bjerkholt
|
|
Director
|
|
May 29, 2009 |
|
|
|
|
|
/s/ Ricardo B. Levy
Ricardo B. Levy, Ph.D.
|
|
Director
|
|
May 29, 2009 |
|
|
|
|
|
/s/ Roger M. Perlmutter
Roger M. Perlmutter, M.D.
|
|
Director
|
|
May 29, 2009 |
|
|
|
|
|
/s/ John J. Schwartz
John J. Schwartz, Ph.D.
|
|
Director, Chairman of the Board
|
|
May 29, 2009 |
|
|
|
|
|
/s/
Irving L. Weissman
Irving L. Weissman, M.D.
|
|
Director
|
|
May 29, 2009 |
II-4
EXHIBIT INDEX
The following is a list of exhibits filed as part of this registration statement:
|
|
|
Exhibit |
|
Description |
4.1
|
|
Specimen common stock Certificate (incorporated by reference to
the registrants Registration Statement on Form S-3, File No.
333-117360) |
|
|
|
5.1*
|
|
Opinion of Ropes & Gray, LLP |
|
|
|
23.1
|
|
Consent of Ropes & Gray LLP (included in Exhibit 5.1) |
|
|
|
23.2*
|
|
Consent of Grant Thornton LLP |
|
|
|
24.1
|
|
Power of attorneyincluded on the signature page |
II-5